1. Home
  2. SLN vs MDV Comparison

SLN vs MDV Comparison

Compare SLN & MDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • MDV
  • Stock Information
  • Founded
  • SLN 1994
  • MDV 2015
  • Country
  • SLN United Kingdom
  • MDV United States
  • Employees
  • SLN N/A
  • MDV N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • MDV Transportation Services
  • Sector
  • SLN Health Care
  • MDV Consumer Discretionary
  • Exchange
  • SLN Nasdaq
  • MDV Nasdaq
  • Market Cap
  • SLN 165.3M
  • MDV 149.1M
  • IPO Year
  • SLN N/A
  • MDV 2022
  • Fundamental
  • Price
  • SLN $5.41
  • MDV $14.08
  • Analyst Decision
  • SLN Buy
  • MDV
  • Analyst Count
  • SLN 5
  • MDV 0
  • Target Price
  • SLN $32.60
  • MDV N/A
  • AVG Volume (30 Days)
  • SLN 170.8K
  • MDV 52.0K
  • Earning Date
  • SLN 05-08-2025
  • MDV 05-07-2025
  • Dividend Yield
  • SLN N/A
  • MDV 8.23%
  • EPS Growth
  • SLN N/A
  • MDV N/A
  • EPS
  • SLN N/A
  • MDV N/A
  • Revenue
  • SLN $27,701,000.00
  • MDV $46,738,000.00
  • Revenue This Year
  • SLN N/A
  • MDV $2.60
  • Revenue Next Year
  • SLN N/A
  • MDV $4.56
  • P/E Ratio
  • SLN N/A
  • MDV N/A
  • Revenue Growth
  • SLN N/A
  • MDV N/A
  • 52 Week Low
  • SLN $1.97
  • MDV $13.62
  • 52 Week High
  • SLN $22.47
  • MDV $18.11
  • Technical
  • Relative Strength Index (RSI)
  • SLN 64.31
  • MDV 37.87
  • Support Level
  • SLN $4.69
  • MDV $14.06
  • Resistance Level
  • SLN $6.35
  • MDV $14.64
  • Average True Range (ATR)
  • SLN 0.53
  • MDV 0.37
  • MACD
  • SLN 0.08
  • MDV -0.01
  • Stochastic Oscillator
  • SLN 62.25
  • MDV 1.77

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About MDV Modiv Industrial Inc. Class C

Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.

Share on Social Networks: